中國奧園(03883.HK)附屬中標奧園美谷 總代價10.2億人幣
中國奧園(03883.HK)早前公佈,旗下奧園美谷(000615.SZ)以底價10億元人民幣(下同)標售附屬,並已指定間接全資附屬深圳凱弦爲投標人蔘與公開招標及向北交所提交投標申請。
公司公佈,公開招標於週二(13日)完成,深圳凱弦獲北交所通知,其以總代價10.2億元成功競得目標附屬公司股權,奧園美谷向深圳凱弦轉讓目標附屬公司股權的正式股權轉讓協議已於同日籤立,須待奧園美谷股東批準及相關監管部門的批準方可作實。
公司指,由於交易是公司集團內部重組的一部分,完成股權轉讓協議將導致其的若幹中間股東出現變動,而其財務業績將繼續於公司之財務報表綜合入賬,並將繼續爲公司附屬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.